跳至主要内容
临床试验/EUCTR2010-021382-78-ES
EUCTR2010-021382-78-ES进行中(未招募)不适用

Dose radiotherapy for lung cancer treatment.

Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)0 个研究点开始时间: 2010年8月9日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • a) Men or women who are between 18 and 65 years of age
  • b)Subjects with histologically or cytologically confirmed non-small cell carcinoma
  • c)Stage III
  • d)Karnofsky index = 70 %.
  • e)Forced Expiratory Volume in 1 second (FEV1) equal or greater than 1 Liter.
  • f)Measurable disease on CT scan of radiotherapy planning.
  • g)Lung percentage (both lungs excluding PTV or planned volume) that will recive a dose > 20 Gy (V20 ) must be less or equal of 30 %.
  • h)The esophagus volume vill be delimited withoth excluding PTV. The percentage of esophagus that will recive a dose > 60 Gy (V60) mus be less or equal to 30% and the mean dose in esophagus (MED) less or equal to 34 Gy.
  • i) Concomitanr chemotherapy.
  • j) Biochemistry and blood analysis. Neutrophils = 1500/µl; platelets = 100000/µl; creatinine = 2 mg/dl, hepatic transaminases < 2,5 times the upper limit of normality, bilirubin < 1,5 times upper limit of normality; alkaline phosphatase < 2,5 times the upper limit of normality.
  • k) Women must commit to consistent and correct use of an acceptable method of birth control.
  • l) Subject with a weigth loss <10% in the previous three months of the disgnosis.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 42
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • a)Small-cell carcinoma
  • b)Pleural or pericardic effusion with positive cytology
  • c)Supraclavicular adenopathy positive
  • d)Superior vena cava syndrome
  • e)Previous thoracic radiation.
  • f)Sensitive neuropathy > grade I following NCI CTCv 3.0 criteria
  • g)Severe comorbididy (acute myocardial infacrtion within 3 nmonth of inclusion, cardiac arrithmia or non-controlled hypertension )
  • h)Treatments that can interfere with the pharmacokinetic or pharmacodynamic of (18F)-FMISO.
  • i)Pregnant or breast-feeding females
  • j)Subjects older than 65 years.
  • k)Subjects with renal and/or hepatic function impairment or failure. A renal impairment is considered if serum creatinine = 2 mg/dl and an hepatic impairment is diagnosed if bilirubin = 1,5 times upper limit normal and or tranbaamionas (ASAT-ALAT) = 2,5 times the upper limit of normality.

研究者

相似试验